Survival and glycemic control in patients with coexisting lymphoma and diabetes: a case–control analysis | Zendy

Bria Rice | Zendy; Matthew Buras | Zendy; Heidi E. Kosiorek | Zendy; Kyle Coppola | Zendy; Shailja B Amin | Zendy; Patricia M Verona | Zendy; Curtiss B. Cook | Zendy; Nina J. Karlin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Survival and glycemic control in patients with coexisting lymphoma and diabetes: a case–control analysis

Author(s) -

Bria Rice,

Matthew Buras,

Heidi E. Kosiorek,

Kyle Coppola,

Shailja B Amin,

Patricia M Verona,

Curtiss B. Cook,

Nina J. Karlin

Publication year - 2020

Publication title -

future science oa

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.825

H-Index - 23

ISSN - 2056-5623

DOI - 10.2144/fsoa-2020-0100

Subject(s) - glycemic , medicine , diabetes mellitus , lymphoma , survival analysis , oncology , gastroenterology , endocrinology

Aim: We examined the effect of diabetes on survival in patients with lymphoma and the effect of lymphoma on glycemic control. Patients & methods: Patients with lymphoma with and without diabetes (2005–2016) were retrospectively identified and matched 1:1. Overall survival and progression-free survival were estimated by the Kaplan–Meier method. Hemoglobin A 1c (HbA 1c ) and glucose levels during the year after cancer diagnosis were compared by mixed models. Results: For patients with diabetes, mean HbA 1c during the year after lymphoma diagnosis was 6.7%. Estimated 5-year progression-free survival for patients with versus without diabetes was 63% (95% CI: 53–76%) versus 58% (95% CI: 46–71%) (p = 0.42). Conclusion: Lymphoma and its treatment did not affect glycemic control. Diabetes did not decrease lymphoma-specific survival.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research